ArticleFrontiers in oncology2021

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.

Yongsheng Ruan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.